Human Psychopharmacology-Clinical and Experimental

Papers
(The TQCC of Human Psychopharmacology-Clinical and Experimental is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls30
The rise of new psychoactive substances and psychiatric implications: A wide‐ranging, multifaceted challenge that needs far‐reaching common legislative strategies26
Structured review of the use of the Arizona sexual experiences scale in clinical settings19
A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans17
Psilocybin occasioned mystical‐type experiences16
N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine14
The effect of cannabidiol on simulated car driving performance: A randomised, double‐blind, placebo‐controlled, crossover, dose‐ranging clinical trial protocol13
Alpha7 nicotinic‐N‐methyl‐D‐aspartate hypothesis in the treatment of schizophrenia and beyond11
Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta‐analysis11
Estimated model of psychotropic polypharmacy for bipolar disorder: Analysis using patients' and practitioners' parameters in the MUSUBI study10
Gabapentinoids for treatment of alcohol use disorder: A systematic review and meta‐analysis10
Anabolic androgenic steroids used as performance and image enhancing drugs in professional and amateur athletes: Toxicological and psychopathological findings10
How does ayahuasca work from a psychiatric perspective? Pros and cons of the entheogenic therapy10
Comparison of potential psychiatric drug interactions in six drug interaction database programs: A replication study after 2 years of updates10
Sceletium tortuosum (Zembrin®) ameliorates experimentally induced anxiety in healthy volunteers9
Safety and cardiovascular effects of multiple‐dose administration of aripiprazole and olanzapine in a randomised clinical trial9
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment‐resistant depression9
Potential processes of change in MDMA‐Assisted therapy for social anxiety disorder: Enhanced memory reconsolidation, self‐transcendence, and therapeutic relationships9
Clozapine‐induced agranulocytosis in Japan: Changes in leukocyte/neutrophil counts before and after discontinuation of clozapine8
Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients8
Elevated serum levels of TNF‐α, IL‐6, and IL‐18 in chronic methamphetamine users8
Kava drinking in traditional settings: Towards understanding effects on cognitive function8
A phase 1 double‐blind, placebo‐controlled study of zuranolone (SAGE‐217) in a phase advance model of insomnia in healthy adults8
Preliminary comparative analysis of kynurenine pathway metabolites in chronic ketamine users, schizophrenic patients, and healthy controls8
The effectiveness of long‐acting injectable antipsychotics versus oral antipsychotics in the maintenance treatment of outpatients with chronic schizophrenia8
Effectiveness, tolerability, and dropout rates of vortioxetine in comorbid depression: A naturalistic study7
Baclofen modulates cardiovascular responses to appetitive cues in treatment‐seeking alcohol use disorder individuals7
Inverse correlation between plasma 2‐arachidonoylglycerol levels and subjective severity of depression7
Progesterone loading as a strategy for treating postpartum depression7
High‐dose Vitamin B6 supplementation reduces anxiety and strengthens visual surround suppression7
Ayahuasca may help to improve self‐compassion and self‐criticism capacities7
Effects of ayahuasca on the endocannabinoid system of healthy volunteers and in volunteers with social anxiety disorder: Results from two pilot, proof‐of‐concept, randomized, placebo‐controlled trials7
Coprescription of mood stabilizers in schizophrenia, dosing, and clinical correlates: An international study7
Childhood maltreatment and clinical response to mood stabilizers in patients with bipolar disorder7
Effects of solriamfetol on on‐the‐road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea6
Sex differences in the prevalence and clinical correlates of hyperhomocysteinemia in patients with bipolar disorder6
Neuroendocrine effects of naltrexone versus nalmefene in humans6
Serotonin transporter availability, neurocognitive function and their correlation in abstinent 3,4‐methylenedioxymethamphetamine users6
Effect of crocin versus fluoxetine in treatment of mild to moderate obsessive‐compulsive disorder: A double blind randomized clinical trial6
Assessing the validity of eyelid parameters to detect impairment due to benzodiazepines6
Role of serotonin transporter and receptor gene polymorphisms in treatment response to selective serotonin reuptake inhibitors in major depressive disorder6
How prevalent and severe is addiction on GABAmimetic drugs in an elderly German general hospital population? Focus on gabapentinoids, benzodiazepines, and z‐hypnotic drugs5
The safety of agomelatine in standard medical practice in depressed patients: A 26‐week international multicentre cohort study5
Drug‐induced tics: An observational postmarketing study5
Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study5
Effect of venlafaxine dosage, valproic acid concentration, sex, and age on steady state dose‐corrected concentrations of venlafaxine and O‐desmethylvenlafaxine: A retrospective analy5
Melatonin and melatonin‐agonists for metabolic syndrome components in patients treated with antipsychotics: A systematic review and meta‐analysis5
Restless Legs Syndrome among patients receiving antipsychotic and antidepressant drugs5
0.10234808921814